Regeneron Pharmaceuticals vs Omnicom Group
Side-by-side comparison of AI visibility scores, market position, and capabilities
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Advertising holding company with $15.7B FY2024 revenue; $13.5B IPG merger announced Dec 2024 to create world's largest ad group; Omni AI data platform; BBDO, DDB, TBWA flagship agencies.
About
Omnicom Group is one of the world's largest holding companies for advertising, marketing, and communications services, founded in 1986 through the merger of BBDO, Doyle Dane Bernbach, and Needham Harper Worldwide, and headquartered in New York City. The company trades on NYSE (OMC) and reported $15.7 billion in revenues for FY2024, employing approximately 100,000 professionals across more than 70 countries. CEO John Wren has led Omnicom since 1997, navigating the digital transformation of advertising from traditional media to programmatic, social, and AI-driven marketing. In December 2024, Omnicom announced the planned acquisition of Interpublic Group (IPG) in an all-stock deal valued at approximately $13.5 billion, which if completed would create the world's largest advertising holding company with over $25 billion in combined revenues.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.